|  | 
      
      
        
          | WHAT IS A PLATELET? 
 A platelet is a cloud-shaped blood cell, neither related to 
                    the red blood cell line nor the white blood cell line. Platelets 
                    act in the clotting of blood in that they home to damaged 
                    areas of blood vessels, and “aggregate” there, meaning that 
                    they pile onto each other and bind, forming a small plug to 
                    seal the hole in the leaking blood vessel. Of course, large 
                    tears are too big for platelets to seal and there are other 
                    blood clotting mechanisms besides platelet aggregation but 
                    when it comes to small bleeds and normal blood vessel wear 
                    and tear, platelets are the star of the show.
 
 There is a saying that “platelets are vascular integrity and 
                    vascular integrity is platelets.”
 
 A small bleed unstaunched by a platelet aggregation quickly 
                    becomes a large bruise. Spontaneous bruising (in other words 
                    visible bruising from the normal wear and tear of one’s body) 
                    is a sign of reduced platelet numbers or poor platelet function.
 
 
 THE LIFE AND TIMES OF JOE 
                    PLATELET 
 We would like to present a more detailed explanation of a 
                    platelets life from beginning to end. Platelets come from 
                    the bone marrow where a large (actually gigantic relative 
                    to the red and white blood cell precursors) cell called a 
                    “megakaryocyte” spits off little active pieces of itself. 
                    These pieces are platelets, ready to enter the circulation 
                    where they will live for an average of 8-12 days (in the dog) 
                    or 6-8 days (in a human) before a bleeding capillary calls 
                    them to their destiny. At any given time some 200,000-500,000 
                    platelets are on patrol in the circulation, though only about 
                    50,000 are considered the bare minimum to prevent spontaneous 
                    bruising and bleeding. About 1/3 of the circulating platelets 
                    are actually stored in the spleen like boats in a harbor, 
                    ready to mobilize if necessary. When platelets become too 
                    old to be useful, the spleen has special cells called “phagocytes” 
                    which essentially eat old cells and recycle their inner materials.
 
                    
 IMMUNE-MEDIATED PLATELET DESTRUCTION
 
 For reasons unknown, platelets can be mistaken by the immune 
                    system as invaders. When this happens, antibodies coat the 
                    platelets and the spleen’s phagocytes remove them in numbers 
                    up to 10 times greater than the normal platelet removal rate. 
                    The megakaryocytes in the bone marrow respond by getting larger 
                    and growing in numbers so that they may increase their production 
                    of platelets. The platelets produced under these circumstances 
                    tend to be larger and more effective than normal platelets 
                    and are called “stress platelets.” The bone marrow attempts 
                    to overcome the accelerated platelet destruction rate; unfortunately, 
                    with immune-mediated destruction occurring, a human platelet 
                    can expect to survive only one day in the circulation instead 
                    of its normal 6-8 days. If antibody levels are very high, 
                    a platelet may survive only minutes or hours after its release 
                    from the bone marrow and, making matters worse, antibody coated 
                    platelets still circulating do not function normally. This 
                    is balanced by the especially effective stress platelets entering 
                    the scene so that overall it is hard to predict how the balance 
                    will work out in a given patient.
 
 
 WHAT WOULD CAUSE THE IMMUNE 
                    SYSTEM TO GET SO CONFUSED? 
 In many cases, a cause is never found; however, in cases a 
                    primary reaction in the immune system precedes the platelet 
                    destruction. For example, immune destruction of some other 
                    stimulus could be occurring. A blood parasite, tumor, drug, 
                    or other cell type (as in lupus or immune-mediated red cell 
                    destruction) might all generate an antibody response. As antibodies 
                    are produced in response to the surface shapes of the “enemy” 
                    cell, some of the surface shapes may unfortunately resemble 
                    “self” shapes such as shapes on the surface of platelets.
 
 WHAT HAPPENS TO THE PATIENT?
 
 The usual patient is a middle-aged dog. Poodles appear to 
                    be predisposed though Cocker Spaniels and Old English Sheepdogs 
                    also seem to have a higher than average incidence of this 
                    condition.
 
 Spontaneous bruising is the major clinical sign. The gums 
                    and oral surfaces or on the whites of the eyes are a obvious 
                    areas to check as is the hairless area of the belly. Small 
                    spots of bruising in large conglomerations called “petecchiae” 
                    (“pet-TEEK-ee-a”) are the hallmark sign. A large, purple expansive 
                    bruise might also be seen. This is called “ecchymosis.” Large 
                    internal bleeds are not typical of platelet dysfunction, though 
                    bleeding small amounts in urine, from the nose, or rectally 
                    may also indicate a platelet problem.
 
 When these sorts of signs are seen, a platelet count is drawn, 
                    along with usually an array of clotting parameters, red blood 
                    cell counts to assess blood loss, and other general metabolic 
                    blood tests. Since testing to detect actual anti-platelet 
                    antibodies is not available, the veterinarian must determine 
                    if any other possible causes of low platelet count make sense.
 
 OTHER CAUSES OF PLATELET DYSFUNCTION
 
 Dramatic reduction in platelet numbers is almost always caused 
                    by immune-mediated destruction, though certain tick-borne 
                    blood parasites could also be responsible:
 Very low platelet counts can also occur in response to the suppression of megakaryocytes within the bone marrow. This might be caused by: Disseminated Intravascular Coagulation is a life-threatening disastrous uncoupling of normal blood clotting and clot dissolving functions in the body and one of its hallmark signs is a drop in platelet count (along with a constellation of other signs).
 If platelet numbers are normal but it is obvious that platelet function is not, some other causes to look into might include:
 
            
            
            THERAPY FOR IMMUNE MEDIATED PLATELET DESTRUCTION
            
            
            
            
 Once a tentative diagnosis of immune-mediated platelet destruction has been made, the goal in therapy is to stop the phagocytes of the spleen from removing the antibody-coated platelets and cutting off antibody production. This, of course, means suppression of the immune system using whatever combination of medication seems to work best for the individual patient.
 
              
                
                
                Prednisone 
                 or 
                
                
                  Dexamethasone 
            
            
 These steroid hormones are the first line of defence and, often, all that is necessary in bringing platelet counts back up. Unfortunately, long term use should be expected and this means steroid side effects are eventually inevitable: excessive thirst, possible urinary tract infection, panting, poor hair coat etc. The good news is that these effects should resolve once medication is discontinued; further, if side effects are especially problematic, other medications can be brought in to reduce the dose of steroid needed.
 
 Vincristine
 
 This injectable medication is mildly immune suppressive but also seems to stimulate a sudden burst of platelet release from the marrow megakaryocytes. The platelets released in response to vincristine contain a phagocyte toxin so that when they are ultimately eaten by spleen phagocytes, the phagocytes will die. While repeated injections of vincristine ultimately do not yield the same effect, at least a one time dose may be extremely helpful. One should note that vincristine is extremely irritating if delivered outside of the vein. It must be given IV cleanly or the overlying tissue will slough.
 
 Androgens
 
 Male hormones may have some masculinizing side effects but they do seem to cut production of anti-platelet antibodies.  It also seems to
                synergise with the corticosteroid hormones like prednisone and dexamethasone. Danazol has been the androgen typically recommended in the treatment of immune-mediated platelet destruction with weight gain being the most common side effect.
 
 Azathioprine 
 or  Cyclophosphamide
 
 These are stronger immune suppressive agents typically used in cancer chemotherapy.  If steroid side effects are unacceptable or if the patient does not respond to steroids alone, one of these medications may be indicated. Cyclosporine, a newer medication made popular in organ transplantation, also may be used but expense has been problematic.
 
              
                
                  TRANSFUSION?
                  
                
              
                
 One might think that a transfusion of blood or at least “platelet rich plasma” might be helpful in the treatment of a platelet dysfunction. The problem is that platelets do not survive well after removal from a blood donor. One has about 12 hours to deliver the freshly withdrawn blood to the recipient before the platelets become inactive. After the platelets are delivered they are likely to live only hours. In general, most efforts are spent on establishing immune suppression.
 
 GAMMA GLOBULIN TRANSFUSION
 
 Gamma globulins are blood proteins including antibodies. Human gamma globulin appears to occupy the phagocyte antibody binding site so that coated platelets cannot be grabbed out of the circulation. This has been a promising therapy for both humans and dogs but is generally prohibitively expensive.
 
 SPLENECTOMY
 
 If medication simply does not work or the condition keeps recurring once medications are discontinued, the solution may be to simply remove the spleen.
                After all, this is where the phagocytes removing the platelets are primarily located. In humans, immune-mediated platelet destruction is generally treated with splenectomy first.
                Response in dogs has not been as predictably good thus in veterinary medicine it is generally one of the last therapies invoked.
 
 Marvista Vet
 |  
          |  
 |  
          | IMMUNE MEDIATED THROMBOCYTOPENIA
            (IMTP) |  
          | What is thrombocytopenia? 
            
            The term thrombocytopenia refers to a condition where a patient has lower than normal levels of circulating platelets. This may be due to increased loss (i.e. hemorrhage), increased destruction (i.e. immune disease), increased consumption (i.e. clotting abnormalities) or decreased production (i.e. disease within the bone marrow). Immune mediated destruction of platelets is one of the more common problems we see here.
 
 Why are platelets important?
 Platelets are cells within the blood that play a critical role in normal blood  clotting functions. They are produced in the bone marrow (like the red and white blood cells) and are then released into the circulation.
 
 What are the causes of IMTP?
 Immune mediated plated destruction can be due to a variety of underlying problems that trigger an abnormal immune response. Things such as infections (bacterial, viral), drugs, certain cancers, etc have all been implicated as potential causes of IMTP. It is also possible that no underlying problem is found in which case it is called idiopathic IMTP. This is the most common cause of life threatening thrombocytopenia in dogs. In order to diagnose the idiopathic form of the disease however, the other potential causes need to be ruled out.
 
 What are the signs of IMTP?
 Because thrombocytopenia leads to problems with normal clotting, the most common signs you may notice at home are bruising, blood in the stool or the urine or nose bleeds. In some instances thrombocytopenia can lead to bleeding into the abdomen, chest, brain or spinal cord. In these cases clinical symptoms may include labored breathing, abdominal distension or neurologic signs.
 
 How is IMTP diagnosed?
 Routine blood tests will show low platelet levels however the key is in looking for a cause for the low platelets. Your veterinarian may perform blood tests to look for specific infectious diseases such as Ehrlichia or heartworms. Since cancer is also a potential trigger of this disease your veterinarian may perform chest x-rays or an abdominal ultrasound.
 
 If no underlying cause is found then a diagnosis of primary IMTP is made and immunosuppressive therapy is begun.
 
 How is IMTP treated?
 The mainstay of therapy, aside from treating the underlying cause, is immunosuppressive therapy. Prednisone is one of the main medications used but there are other drugs that may be required as well (i.e. Azathioprine, Cyclophosphamide). Regardless of the type of therapy that your veterinarian chooses, frequent rechecks will be an extremely important part of the plan.
 
 If the thrombocytopenia is severe, your veterinarian may recommend hospitalizing your pet for observation and more aggressive treatment. Unfortunately, a blood transfusion will not supply enough platelets to reverse thrombocytopenia. If the low platelets however have led to blood loss and subsequent anemia, then a transfusion may be indicated.
 
 The prognosis with IMTP can be quite variable and depends on the underlying cause, response to therapy or drug complications. Overall, if there is no severe underlying disease and your pet responds well to therapy, the prognosis is generally good although lifelong medication may be required.
 
 
 Gold Coast Veterinary Specialists
 |  
          |  
 |  
          | THROMBOCYTOPENIA, PRIMARY IMMUNE MEDIATED |  
          | Definition Immune-mediated destruction of platelets
 
 Pathophysiology
 Autoimmune process in which antibodies develop against platelet antigens. Antibodies bind to the antigen on the platelet surface, and then the antibody-coated platelets are prematurely removed from the circulation by the macrophage phagocytic system.
 
 Systems Affected
 If the platelet count is low enough (< 40,000/ µl) hemorrhage can occur into any organ
 system. Systems commonly recognized as
 affected clinically include integumentary,
 gastrointestinal, respiratory, and urinary.
 
 Genetics
 N/A
 
 Incidence and Prevalence
 In a recent study at North Carolina State Veterinary Teaching Hospital, 5.2% of dogs admitted to the hospital had thrombocytopenia. In patients with thrombocytopenia, 2.8% were thought to have primary immune-mediated thrombocytopenia. In similar studies in cats, 1.2% had thrombocytopenia, and 2% of these were thought to have immune-mediated thrombocytopenia.
 
 Geographic Distribution
 N/A
 
 Signalment
 
 Species
 Breed Predilection 
              Cocker Spaniel, Poodle, Old English Sheepdog, and, possibly, German ShepherdNo known breed predilection in cats  Mean Age and Range 
              Mean age in dogs, 6-7 yearsAge range in dogs, 7 months to 14 years Predominant SexMore common in female dogs
 
 Signs
 
 Historical Findings
 
              Hemorrhages in the skin and mucous membranesExcessive hemorrhage associated with a mild traumatic eventSpontaneous epistaxisVomiting bloodBlood in the stoolLethargy, weakness, and collapseBleeding less commonly seen in cats Physical Examination Findings 
              Petechial and ecchymotic hemorrhages in the skin and mucous membranesEpistaxisMelena, hematochezia, or hematemesisHematuriaPale mucous membranesLethargy, weakness, and collapseScleral and retinal hemorrhages and hyphemaDyspneaHeart murmurNeurologic signs  Causes Idiopathic
 
 Risk
            Factors
 Unknown
 
 DIAGNOSIS
             
 
            
            -------------------------
 
 Differential
            Diagnosis
 
              Disseminated intravascular coagulation. To rule out, perform coagulation profileBlood loss as a result of trauma or secondary to vitamin K antagonist (thrombocytopenia is mild)Low platelet production (thrombocytopenia is usually moderate to severe)Evaluate animal for other cytopenias such as nonregenerative anemia and leukopenia, and perform examination of bone marrow aspirate and core biopsy to identify the type of primary bone marrow disease.Myeloproliferative disorders and FeLV infection commonly cause thrombocytopenia in cats. FIV sometimes causes thrombocytopenia. Perform FeLV
                and FIV tests to rule out these diseases.Hepatomegaly and splenomegaly (mild thrombocytopenia)Secondary immune-mediated thrombocytopenia. Clinical and laboratory findings are identical to those of primary immune-mediated thrombocytopenia. Causes of the former include drugs, neoplasms, infectious diseases (e.g., ehrlichiosis, FeLV infection, and, probably, Rocky Mountain spotted fever), and immune-mediated diseases such as systemic lupus erythrematosis and immune-mediated hemolytic anemia. Perform serum titers to rule out ehrlichiosis and Rocky Mountain spotted fever. Perform ANA test for systemic lupus erythematosis. Evaluate blood film for spherocytes and agglutination to help determine if patient has immune-mediated hemolytic anemia.Thrombocytopenia develops secondarily to many infectious diseases. CBC/Biochemistry/Urinalysis 
              In most patients, severe thrombocytopenia (platelet count < 20,000/µl); not uncommon to see platelet counts in the 1000-5000/µl rangeMild to moderate anemia often with hypoproteinemia. If there has been enough time for the bone marrow to respond, the anemia is regenerative.Neutrophilia in some patientsHematuria  Other
            Laboratory Tests 
              Antiplatelet antibody test--if positive and other causes of thrombocytopenia are ruled out, it strongly supports the diagnosis. False-negatives do occur.Antimegakaryocyte antibody test--if positive and other causes of thrombocytopenia are ruled out, it strongly supports the diagnosis. False-negatives do occur. This test may be less sensitive than the antiplatelet antibody test.Mean platelet volume. Microthrombocytosis (mean platelet volume, < 5.4 fl) has been documented in some patients and usually is seen early in the disease process. As the disease progresses, the platelets increase in size resulting in macrothrombocytosis. ImagingUsed to rule out other causes of thrombocytopenia
 
 Other
            Diagnostic Procedures
 Bone marrow aspiration with or without core biopsy. Cytological evaluation of the bone marrow is helpful to make sure that thrombocytopenia is not caused by low production. If megakaryocytes are readily observed, then low production of platelets is unlikely. Selective immune-mediated destruction of megakaryocytes is rare. Erythroid and megakaryocytic hyperplasia is seen in some patients.
 
 Gross and
            Histopathologic Findings
 
              Petechial and ecchymotic hemorrhages in the mucous membranes, skin, and serosal surfacesHemorrhage into any organ, especially the gastrointestinal, respiratory, and urinary systemsPossibly, erythroid and megakaryocytic hyperplasia in the bone marrow  TREATMENT
            
            
            ----------------------- Inpatient
            Versus OutpatientIf the patient has severe hemorrhage, stabilize and then treat as an outpatient.
 
 Activity
 Restricted
 
 Diet
 N/A
 
 Client Education
 
              Animals with severe hemorrhage should be brought to the hospital for monitoring and treatment.Fatal hemorrhage is more likely if exercise is not restricted.  Surgical
            ConsiderationsSplenectomy may be done in cases that are refractory to medical treatment.
 
 MEDICATIONS ---------------------
 Drugs and Fluids 
              Prednisone or prednisolone (1-2mg/kg PO q12h for at least 2 weeks or until markedimprovement in the platelet count is seen). Once the platelet count is within the normal reference range, the dosage should be gradually tapered over weeks to months.
Dexamethasone can be used initially (0.1-0.2 mg/kg IV q12h).If the patient is unresponsive to corticosteroid, vincristine can be added (0.02-0.03 mg/kg or 0.5-0.75 mg/m2 IV once a week).In addition to the vincristine or alternatively to the vincristine, cyclophosphamide can be added (2.2 mg/kg or 50 mg/m2 PO q24h 3-4 days per week).Blood transfusions if the anemia is severe and causing clinical signsPlatelet-rich plasma may be given if available.  ContraindicationsNone
 
 Precautions
 
              If glucocorticoid-associated, gastric ulceration develops, drugs such as sucralfate can be usedLong-term treatment with corticosteroids can cause iatrogenic hyperadrenocorticism.Cyclophosphamide can cause bone marrow suppression and sterile hemorrhagic cystitis.
Vincristine is irritating if injected perivascularly. It can also cause constipation, peripheral neuropathy, and bone marrow suppression.  Possible
            InteractionsN/A
 
 Alternate Drugs
 
              Dogs -- danazole (5 mg/kg PO q12h) can be used concurrently with glucocorticoids. Do not use danazole in cats.Dogs -- azathioprine (2 mg/kg or 50 mg/m2 PO q24h-q48h) can be used to maintain remission.  FOLLOW-UP---------------------------
 Patient
            Monitoring
 Platelet count daily until the count is >50,000/µl and then weekly until the count returns to the normal range (in some patients the count will not return to the normal range). If the owner notices severe bleeding, the patient should be brought in for evaluation.
 Prevention/AvoidanceMinimize stress that may initiate recurrence.
 
 Possible
            Complications
 Severe hemorrhage and death
 
 Expected
            Course and Prognosis
 If the thrombocytopenia is severe and cannot be quickly improved by immunosuppressive therapy, animals may succumb as a result of fatal hemorrhage. Approximately 25% of patients referred to a veterinary teaching hospital died or were euthanatized. Of the patients that survived, approximately 50% had acute disease requiring only one course of immunosuppressive drugs, and 50% had chronic disease that recurred months to years later. In patients with acute disease that respond to corticosteroids, the platelet count increases in several days.
 
 MISCELLANEOUS
            ---------------------
 
 Associated
            Conditions
 Immune-mediated hemolytic anemia
 
 Age Related Factors
 None
 
 Zoonotic Potential
 None
 
 Pregnancy
 Use of immunosuppressive drugs may cause damage to the fetus.
 
 Synonyms
 
              Idiopathic thrombocytopenia purpuraIdiopathic immune-mediated thrombocytopenia VetMedCenter.com
 |  
          |  
 |  
          | :: The Immune System ::  Vaccinations & Minimum Disease Prevention :::: Nutrition & the Immune System ::
 Immune Deficiencies & Autoimmunity ::
 :: Immune-Mediated Thrombocytopenia (IMTP) ::
 |  
          |  
 |  
      
      
        
          | LINKS TO ARTICLES ON OTHER SITES |  
          |  |  
          |  |  
          |  |  
          | 
 |  |  |